Targeted Covalent Inhibitors for the Treatment of Malaria?
Malaria is a vector-borne disease caused by protozoan parasites of the genus . According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of att...
Saved in:
| Published in: | ACS infectious diseases Vol. 6; no. 11; p. 2815 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
13.11.2020
|
| ISSN: | 2373-8227, 2373-8227 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Malaria is a vector-borne disease caused by protozoan parasites of the genus
. According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of attention and several TCI-based drugs have been approved across different therapeutic areas. For malaria, surprisingly, this approach has not been explored in depth even though lot of advancements have been made in understanding the biology of the parasite. Herein, we present our views on exploring TCIs as a new class of antimalarial agents. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 2373-8227 2373-8227 |
| DOI: | 10.1021/acsinfecdis.0c00684 |